

Supplementary Table 1. Clinical and pathological characteristics of 365 HCC patients.

Parameters	Variables	N	%
VETC	positive	87	23.84
	negative	278	76.16
LMR	$\leq 7.75$	345	94.52
	$>7.75$	20	5.48
PLR	$\leq 40$	131	35.89
	$>40$	234	64.11
Neutrophils	$\leq 7$	345	94.52
	$>7$	20	5.48
GPR	$\leq 0.17$	80	21.92
	$>0.17$	285	78.08
AAR	$\leq 0.86$	156	42.74
	$>0.86$	209	57.26
ALRI	$\leq 29.75$	266	72.88
	$>29.75$	99	27.12
ANRI	$\leq 12.43$	234	64.11
	$>12.43$	131	35.89
APRI	$\leq 0.21$	184	50.41
	$>0.21$	181	49.59
BLRI	$\leq 21.73$	183	50.14
	$>21.73$	182	49.86

SII	$\leq 545.6$	269	73.7
	$>545.6$	96	23.6
SIRI	$\leq 0.64$	110	30.14
	$>0.64$	255	69.86
ALT	$\leq 40$	186	50.96
	$>40$	179	49.04
AST	$\leq 45$	255	69.86
	$>45$	110	30.14
TB	$\leq 17.1$	290	79.45
	$>17.1$	75	20.55
PT	$\leq 13.5$	351	96.16
	$>13.5$	14	3.84
Gender	female	46	12.6
	male	319	87.4
HBV infection	negative	43	11.78
	positive	322	88.22
Splenomegaly	negative	303	83.01
	positive	62	16.99
Liver cirrhosis	negative	586	78.36
	positive	79	21.64
Tumor number	solitary	317	86.85
	multiple	48	13.15
Ascites	negative	361	98.9

	positive	4	1.1
Tumor envelope	complete	241	66.03
	incomplete	124	33.97
Age		$50.58 \pm 11.22$	
AFP(ln)		$4.71 \pm 3.28$	
Tumor diameter(ln)		1.55(1.13, 1.92)	

VETC: Vessels that encapsulate tumor cluster; LMR: lymphocyte to monocyte ratio; PLR: platelet-lymphocyte ratio; GPR:  $\gamma$ -glutamyl transpeptidase to platelet ratio; AAR: AST to ALT ratio; ALRI: AST to lymphocyte ratio index; ANRI: AST to neutrophil ratio index; APRI: AST to platelet ratio index; BLRI: ALT to lymphocyte ratio index; SII: systemic immune-inflammation index; SIRI: systemic inflammation response index.